Tiny trial hopes to tame lupus and more with experimental biologic
NCT ID NCT07193810
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-phase study tests a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that hasn't responded to standard treatments. The main goal is to check safety and find the right dose, with a secondary look at whether it helps control the disease. Because it's so small and early, the results will only hint at whether CC312 might be worth testing in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deyang People's Hospital
RECRUITINGDeyang, Sichuan, 618000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC312 (a biologic drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.
What could go wrong
This is a very early, tiny trial with only 6 participants, so results may not apply to everyone. The main goal is safety, not proof of effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.